This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, non-eHealth) (144) CIHR funded proposals with peer-review reports (Canada) (37)

Published on in Vol 6 , No 8 (2017) :August

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Authors of this article:

Ian Gilron 1 Author Orcid Image ;   Dongsheng Tu 2 Author Orcid Image ;   Ronald Holden 2 Author Orcid Image ;   Tanveer Towheed 2 Author Orcid Image ;   Elizabeth Vandenkerkhof 2 Author Orcid Image ;   Roumen Milev 2 Author Orcid Image
Article Authors Cited by (2) Tweetations (3) Metrics

Journals

  1. Schweiger V, Secchettin E, Castellani C, Martini A, Mazzocchi E, Picelli A, Polati E, Donadello K, Valenti M, Dalle Carbonare L. Comparison between Acupuncture and Nutraceutical Treatment with Migratens® in Patients with Fibromyalgia Syndrome: A Prospective Randomized Clinical Trial. Nutrients 2020;12(3):821 View
  2. Gilron I, Robb S, Tu D, Holden R, Milev R, Towheed T. Combination analgesic development for enhanced clinical efficacy (the CADENCE trial): a double-blind, controlled trial of an alpha-lipoic acid–pregabalin combination for fibromyalgia pain. Pain 2023;Publish Ahead of Print View